Published in Pediatr Neurosurg on July 01, 2000
VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 8.10
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol (2007) 2.85
Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A (2002) 2.45
Diffuse glioma growth: a guerilla war. Acta Neuropathol (2007) 2.11
Endothelial epsin deficiency decreases tumor growth by enhancing VEGF signaling. J Clin Invest (2012) 1.87
Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol (2008) 1.48
Therapeutic targets in malignant glioblastoma microenvironment. Semin Radiat Oncol (2009) 1.11
TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer (2006) 1.03
JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma. Neuro Oncol (2014) 0.97
Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion. PLoS One (2013) 0.95
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J Cell Mol Med (2009) 0.94
In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem (2008) 0.93
Choline-to-N-acetyl aspartate and lipids-lactate-to-creatine ratios together with age assemble a significant Cox's proportional-hazards regression model for prediction of survival in high-grade gliomas. Br J Radiol (2016) 0.91
Mesenchymal migration as a therapeutic target in glioblastoma. J Oncol (2010) 0.89
EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice. Cancer Invest (2011) 0.82
A graphic method for identification of novel glioma related genes. Biomed Res Int (2014) 0.80
Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype. J Signal Transduct (2012) 0.79
The role of semaphorins and their receptors in gliomas. J Signal Transduct (2012) 0.79
Research of shRNAmir inhibitory effects towards focal adhesion kinase expression in the treatment of gastric cancer. Oncol Lett (2014) 0.77
Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. PLoS One (2014) 0.77
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art. Crit Rev Immunol (2014) 0.76
A role for activated Cdc42 in glioblastoma multiforme invasion. Oncotarget (2016) 0.75
Regulation of the hypoxic tumor environment in hepatocellular carcinoma using RNA interference. Cancer Cell Int (2017) 0.75
Bis(4,4'-bipyridine-κN)tetra-kis(nitrato-κO,O')tin(IV). Retraction. Acta Crystallogr Sect E Struct Rep Online (2008) 65.17
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science (1997) 15.48
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Identification of ubiquitin ligases required for skeletal muscle atrophy. Science (2001) 12.98
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev (1998) 12.48
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol (2001) 10.85
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell (1991) 9.54
Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 9.18
Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 9.10
Purification and characterization of hypoxia-inducible factor 1. J Biol Chem (1995) 8.53
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell (1992) 8.20
Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (1999) 6.96
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci U S A (1993) 6.77
Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol (2001) 6.71
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
Essential role for oncogenic Ras in tumour maintenance. Nature (1999) 6.51
Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature (1993) 6.38
FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev (2001) 6.35
Developmentally controlled and tissue-specific expression of unrearranged VH gene segments. Cell (1985) 6.21
Phosphatidylinositol 3'-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J (1992) 5.84
Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature (1984) 5.75
Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell (1991) 5.65
HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol (2001) 5.59
Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med (2000) 5.58
Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol (1996) 5.52
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem (1993) 5.09
Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science (1995) 4.90
Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem (1996) 4.72
An insulin-stimulated protein kinase similar to yeast kinases involved in cell cycle control. Science (1990) 4.63
Oncogenic alterations of metabolism. Trends Biochem Sci (1999) 4.51
Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem (1997) 4.43
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst (2001) 4.27
Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A (2007) 4.27
Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science (1997) 4.26
Development of the primary antibody repertoire. Science (1987) 4.19
Insertion of N regions into heavy-chain genes is correlated with expression of terminal deoxytransferase in B cells. Nature (1984) 4.18
Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron (1996) 4.12
Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science (1999) 4.10
Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol (1986) 4.09
Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature (1997) 4.01
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest (1999) 4.00
Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 3.98
PDGF stimulation of inositol phospholipid hydrolysis requires PLC-gamma 1 phosphorylation on tyrosine residues 783 and 1254. Cell (1991) 3.95
A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell (1993) 3.94
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell (1996) 3.81
Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res (1998) 3.79
Recombination between immunoglobulin variable region gene segments is enhanced by transcription. Nature (1987) 3.74
Increased vascularization in mice overexpressing angiopoietin-1. Science (1998) 3.67
Regulation of genome rearrangement events during lymphocyte differentiation. Immunol Rev (1986) 3.65
Differential expression of myc family genes during murine development. Nature (1986) 3.57
Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science (1994) 3.53
Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides (1986) 3.51
Introduced T cell receptor variable region gene segments recombine in pre-B cells: evidence that B and T cells use a common recombinase. Cell (1986) 3.51
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene (1999) 3.45
Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol (1992) 3.42
Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res (1999) 3.36
Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev (1999) 3.35
Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer (2000) 3.31
Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implications for their mechanism of activation. Proc Natl Acad Sci U S A (1991) 3.31
Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J Neurosci (2001) 3.23
Direct comparison of GAPDH, beta-actin, cyclophilin, and 28S rRNA as internal standards for quantifying RNA levels under hypoxia. Biochem Biophys Res Commun (1999) 3.21
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res (1997) 3.17
NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron (1990) 3.12
The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science (1993) 3.12
Identification of a novel contactin-associated transmembrane receptor with multiple domains implicated in protein-protein interactions. EMBO J (1997) 3.11
PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron (1998) 3.09
VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci (2001) 3.08
Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem (1992) 2.97
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science (1990) 2.91
ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol (2000) 2.90
An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. Mol Cell (1997) 2.89
SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma. EMBO J (1992) 2.82
Generation of deletion and point mutations with one primer in a single cloning step. Biotechniques (2000) 2.81
Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands. Nature (1996) 2.81
Agrin acts via a MuSK receptor complex. Cell (1996) 2.81